MHRA publishes ‘world first’ decentralised manufacturing guidance The guidance will inform the manufacture of medicines with a short shelf-life or highly personalised medicines at sites within or in close proximity to hospitals.…
NHS pharmacogenomics trial expands to 20 sites across England The PROGRESS trial is planned to finish in early 2026, with an impact assessment produced in the fourth quarter of 2025/2026.…
Genetic testing could prevent three-quarters of avoidable side effects of some medicines, study suggests Researchers found that patients experiencing adverse drug reactions to treatments for psychiatric disorders and cardiovascular problems could benefit the most from personalised prescribing with pharmacogenomics.…
Rapid on-site genetic sequencing could help curb antimicrobial-resistant outbreaks, says MHRA Researchers found that rapid on-site genetic sequencing detects bacterial infections within two days, which is “significantly faster“ than traditional methods.…
Nine in ten people would accept a pharmacogenomics test, reveals survey The majority of respondents to a survey said they would be motivated to take a pharmacogenomics test to enhance drug effectiveness and reduce the risk of adverse drug reactions.…
Pharmacogenomics trial expands across England Programme co-ordinators are aiming to recruit a further 1,450 people to the second phase of the PROGRESS trial, which is the first in the UK to introduce genetic testing before prescribing in primary care.…
NICE approves gene-editing sickle cell therapy for NHS in England Exagamglogene autotemcel, also known as exa-cel, is now recommended for NHS use, reversing previous draft guidance.…
One-quarter of patients in pharmacogenomics trial have had prescriptions changed Around 25% of the 400 participants of the 'Progress programme' have been advised to change their prescription following genetic testing.…
Proposed National Pharmaceutical Agency on hold, says Scottish government Exclusive: The Scottish government has confirmed that the scoping phase in the development of a National Pharmaceutical Agency was paused before completion, with no next steps planned.…
More than 2,000 patients tested in UK’s first routine genotyping project for clopidogrel prescribing Exclusive: The genotyping project at NHS Tayside identified 2,300 patients, 29% of whom emerged as ‘poor’ or ‘intermediate’ CYP2C19-clopidogrel metabolisers.…
